Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 with pembrolizumab in metastatic melanoma
NCT03161431Phase 1Active, not recruiting
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SX-682 in melanoma (2 arms), sponsored by Syntrix Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 21 days, Objective Response Rate and 3 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
SX-682
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03161431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161431.